Tectonic Therapeutic, INC Form 4 insider transactions

Tectonic Therapeutic's Chief Business Officer, Marc Schwabish, disposed of 1,619 common shares to cover tax obligations related to restricted stock unit vesting.

Tectonic Therapeutic's Chief Medical Officer, Marcella K. Ruddy, disposed of 2,064 shares of common stock to cover tax obligations related to RSU vesting.

Tectonic Therapeutic CEO Alise Reicin disposed of 4,104 shares of common stock to cover tax withholding obligations related to RSU vesting.

Tectonic Therapeutic's Chief Scientific Officer, Peter McNamara, disposed of 1,748 common shares to cover tax liabilities from RSU vesting.

Alise Reicin, CEO of Tectonic Therapeutic, exercised employee stock options to acquire 10,966 shares of common stock at $2.38 per share under a pre-arranged 10b5-1 plan.

Tectonic Therapeutic's Chief Scientific Officer, Peter McNamara, exercised 7,000 employee stock options at $2.98 per share.

Tectonic Therapeutic's Chief Business Officer, Marc Schwabish, received new equity awards including restricted stock units and stock options.

Tectonic Therapeutic's Chief Scientific Officer, Peter McNamara, acquired 4,550 restricted stock units and 8,260 employee stock options.

Tectonic Therapeutic's CFO, Daniel Lochner, acquired 5,430 restricted stock units and 9,860 employee stock options, increasing his beneficial ownership.

Tectonic Therapeutic's Chief Medical Officer, Marcella K. Ruddy, received grants of restricted stock units and employee stock options on September 25, 2025.

Tectonic Therapeutic CEO Alise Reicin received grants of 14,700 restricted stock units and options for 26,710 shares.

Tectonic Therapeutic, Inc. CEO Alise Reicin reported a disposition of 859 common shares at $19.81 each to cover tax withholding obligations related to vested restricted stock units.

Phillip B. Donenberg, a Director at Tectonic Therapeutic, Inc., acquired 10,200 stock options with an exercise price of $24.48, set to vest by June 2026.

Tectonic Therapeutic, Inc. Director Stefan Vitorovic was granted 10,200 stock options with an exercise price of $24.48, aligning his interests with the company's long-term performance.

Tectonic Therapeutic, Inc. Director Terrance McGuire was granted 10,200 stock options with an exercise price of $24.48, vesting by June 2026 or earlier under specific conditions.

Praveen P. Tipirneni, a Director at Tectonic Therapeutic, Inc., was granted 10,200 stock options with an exercise price of $24.48, vesting based on specific conditions.

Timothy A. Springer, a Director and 10% Owner of Tectonic Therapeutic, Inc. (TECX), has acquired 10,200 stock options with an exercise price of $24.48, signaling continued alignment with shareholder interests.

Director Timothy Springer reports multiple purchases of Tectonic Therapeutic (TECX) common stock between April 9th and April 11th, 2025, increasing his direct and indirect holdings.

Director Timothy Springer reports purchasing shares of Tectonic Therapeutic, Inc., increasing his direct and indirect holdings.

Director Terrance McGuire reports the acquisition of 500,000 shares of Tectonic Therapeutic, Inc. at $17.10 per share.

Director Timothy Springer reports acquisition of Tectonic Therapeutic shares through a private placement and holdings via an LLC.

Daniel Lochner, CFO of Tectonic Therapeutic, purchased 4,617 shares of common stock in a private placement transaction.

Chief Scientific Officer Peter McNamara reports acquisition of restricted stock units and stock options in Tectonic Therapeutic, Inc.

Chief Business Officer Marc Schwabish reports acquiring and disposing of Tectonic Therapeutic shares and stock options.

Chief Financial Officer Daniel Lochner of Tectonic Therapeutic, Inc. reports the acquisition of restricted stock units and stock options.

Chief Medical Officer Marcella K. Ruddy acquired shares and options in Tectonic Therapeutic, Inc. on February 4, 2025.

Alise Reicin, CEO of Tectonic Therapeutic, reports acquisition of shares and options in the company, including restricted stock units and employee stock options.

Marc Schwabish, Chief Business Officer of Tectonic Therapeutic, exercised stock options to acquire 2,700 shares of common stock at $2.38 per share on January 28, 2025.

Tectonic Therapeutic's Chief Business Officer, Marc Schwabish, exercised stock options to acquire 2,000 shares of common stock at $2.38 per share.

Tectonic Therapeutic's CEO, Alise Reicin, acquired shares and stock options, as detailed in a recent SEC Form 4 filing.